4/21
04:31 pm
asnd
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
Medium
Report
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
4/20
08:00 am
asnd
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
Low
Report
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
4/16
10:15 am
asnd
Ascendis Pharma A/S (ASND) had its price target raised by Bank of America Corporation from $262.00 to $292.00. They now have a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (ASND) had its price target raised by Bank of America Corporation from $262.00 to $292.00. They now have a "buy" rating on the stock.
4/9
09:16 am
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wedbush. They now have a $273.00 price target on the stock.
Medium
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wedbush. They now have a $273.00 price target on the stock.
4/8
12:00 pm
asnd
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
Low
Report
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
4/8
08:01 am
asnd
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
Low
Report
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
4/6
04:01 pm
asnd
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
Low
Report
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
4/6
11:33 am
asnd
How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma's (ASND) Pipeline Strategy [Yahoo! Finance]
Low
Report
How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma's (ASND) Pipeline Strategy [Yahoo! Finance]
4/4
08:33 am
asnd
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial [Yahoo! Finance]
Low
Report
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial [Yahoo! Finance]
3/25
05:05 pm
asnd
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization [Yahoo! Finance]
Low
Report
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization [Yahoo! Finance]
3/20
09:28 pm
asnd
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention [Yahoo! Finance]
Low
Report
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention [Yahoo! Finance]
3/17
09:05 am
asnd
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 [Yahoo! Finance]
Low
Report
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 [Yahoo! Finance]
3/17
08:30 am
asnd
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
Low
Report
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
3/16
10:58 am
asnd
Ascendis Pharma A/S (ASND) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (ASND) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/16
08:00 am
asnd
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
Low
Report
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
3/12
08:48 am
asnd
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
Low
Report
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
3/5
05:03 pm
asnd
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by Bank of America Corporation.
Low
Report
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by Bank of America Corporation.
3/4
10:52 pm
asnd
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
Low
Report
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
3/4
10:14 pm
asnd
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]
Low
Report
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]
3/4
09:09 pm
asnd
Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.
Low
Report
Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.
3/4
06:06 am
asnd
Ascendis Wins FDA Approval For Rare Disease Therapy [Yahoo! Finance]
Low
Report
Ascendis Wins FDA Approval For Rare Disease Therapy [Yahoo! Finance]
3/2
09:02 pm
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
3/2
05:00 pm
asnd
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript [Seeking Alpha]
Low
Report
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript [Seeking Alpha]
3/2
04:22 pm
asnd
Ascendis wins FDA approval of dwarfism drug [Yahoo! Finance]
Low
Report
Ascendis wins FDA approval of dwarfism drug [Yahoo! Finance]
3/2
01:05 pm
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wolfe Research.
Low
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wolfe Research.